Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sheila Roser

Clinical Nurse Specialist, Adult Health Munster, IN Clinical Nurse Specialist

NPI 1124525704 CMS profile 10782892

800 MacArthur Blvd Ste 29, Munster, IN 46321

Open in the dashboard

General payments

$1,236

31 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sheila Roser of Munster, IN is reported in the CMS Open Payments database as having received $1,236 across 31 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $143 1
2024 General $445 12
2023 General $81 2
2022 General $508 12
2021 General $60 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheila Roser
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Sheila Roser were reported at $143. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Sheila Roser Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $60 $133 $48–$445 $132
2022 $508 $163 $57–$526 $149
2023 $81 $173 $64–$597 $160
2024 $445 $171 $54–$575 $164
2025 $143 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $960 21 payments
  2. Medtronic, Inc. $148 5 payments
  3. Boston Scientific Corporation $82 3 payments
  4. Amneal Pharmaceuticals LLC $25 1 payment
  5. Bioventus LLC $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,236 31 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $678 17 payments
  2. ETERNA Structural Heart $143 1 payment
  3. INTELLIS ADAPTIVESTIM $87 1 payment
  4. ETERNA Neuromodulation $73 2 payments
  5. PROCLAIM Neuromodulation $66 1 payment
  6. LIORESAL (BACLOFEN) $25 1 payment
  7. Vanta $23 1 payment
  8. Intracept $22 1 payment
  9. SYNCHROMED $22 2 payments
  10. SUPARTZ FX SODIUM HYALURONATE $21 1 payment
  11. Other $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

3,843

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$148,133

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

44.5%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,095 $25,263
Nucynta Tapentadol Hcl Brand 23 $23,151
Buprenorphine Generic 34 $15,448
Belbuca Buprenorphine Hcl Brand 17 $14,894
Butrans Buprenorphine Brand 26 $13,121
Pregabalin Generic 279 $8,950
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 350 $7,857
Gabapentin Generic 489 $7,655
Fentanyl Generic 57 $5,682
Celecoxib Generic 69 $3,831

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$30,768

Medicare's payments for the services billed

Medicare patients

183

Average age 74

Services billed

815

118 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 46%
Depression 43%
Diabetes 42%
Heart failure 38%
COPD 38%
Chronic kidney disease 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record